54 reports of this reaction
2.4% of all DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE reports
#6 most reported adverse reaction
HEADACHE is the #6 most commonly reported adverse reaction for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, manufactured by Major Pharmaceuticals. There are 54 FDA adverse event reports linking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE to HEADACHE. This represents approximately 2.4% of all 2,218 adverse event reports for this drug.
Patients taking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 54 FDA reports for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.4% of all adverse event reports for DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, making it a notable side effect.
If you experience headache while taking DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.